Why the study?
Does rosuvastatin reduce cardiovascular mortality, non-fatal MI, or non-fatal stroke in elderly patients with chronic symptomatic systolic heart failure of ischemic etiology?
Population
Men and women, aged ≥60 years with chronic symptomatic systolic heart failure of ischemic etiology and…
Comparison
Rosuvastatin 10 mg vs Placebo
Design
RCT, randomized, double-blind
Authors
Loading...
Addresses evidence gap for statins in elderly ischemic HF; RCT will deliver first dedicated outcome data to inform use.
Does rosuvastatin reduce cardiovascular mortality, non-fatal MI, or non-fatal stroke in elderly patients with chronic symptomatic systolic heart failure of ischemic etiology?
The CORONA trial is designed to evaluate whether rosuvastatin improves outcomes in elderly patients with ischemic systolic heart failure.
Kjekshus et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: